In France, three varieties of therapeutic plasma are being processed, distributed and delivered, currently; however, many more varieties are in use worldwide, which go by the property of labile blood component or plasma derived medicines. For one type of component (one given name), several devices and bags and so on are used to concur to its process, which makes that one type of therapeutic plasma may significantly differ from one production setting to one other. This may affect (more or less) the component properties as well as the possibly reported adverse events. This review aims thus, firstly at stressing on the difficulty in comparing data obtained in different contexts, and secondly at making the point on future directions to process therapeutic plasma.
Keywords: Adverse events; Effets secondaires; Hemostasis; Hemovigilance; Hémostase; Hémovigilance; Inactivation; Labile blood component; Pathogen inactivation; Plasma derived drug; Plasma thérapeutique; Produits sanguins labiles; Produits sanguins stables; Therapeutic plasma.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.